Research & Literature

Radiotherapy-related arterial intima thickening and plaque formation in childhood cancer survivors detected with very-high resolution ultrasound during young adulthood.

Vatanen A, Sarkola T, Ojala TH, et al.

Pediatric blood & cancer 2015; (62(11)):2000-6 doi:10.1002/pbc.25616.

MIB-1 Index as a Surrogate for Mitosis-Karyorrhexis Index in Neuroblastoma.

Atikankul T, Atikankul Y, Santisukwongchote S, et al.

The American journal of surgical pathology 2015; (39(8)):1054-60 doi:10.1097/PAS.0000000000000478.

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Bosse KR, Maris JM

Cancer 2016; (122(1)):20-33 doi:10.1002/cncr.29706.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, et al.

Pediatric blood & cancer 2016; (63(6)):1019-23 doi:10.1002/pbc.25934.

Dinutuximab: A Review in High-Risk Neuroblastoma.

Hoy SM

Targeted oncology 2016; (11(2)):247-53 doi:10.1007/s11523-016-0420-2.

Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.

Ploessl C, Pan A, Maples KT, Lowe DK

The Annals of pharmacotherapy 2016; (50(5)):416-22 doi:10.1177/1060028016632013.

Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

Mora J

Expert review of clinical pharmacology 2016; (9(5)):647-53 doi:10.1586/17512433.2016.1160775.

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

Hallett RM, Seong AB, Kaplan DR, Irwin MS

Molecular oncology 2016; (10(9)):1461-1472 doi:10.1016/j.molonc.2016.07.012.

Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

Armstrong AE, Danner-Koptik K, Golden S, et al.

Journal of pediatric hematology/oncology 2018; (40(1)):31-35 doi:10.1097/MPH.0000000000000848.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, et al.

Cancer 2017; (123(21)):4224-4235 doi:10.1002/cncr.30873.

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).

Jung SH, Lee JJ, Kim JS, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(5)):923-929 doi:10.1016/j.bbmt.2018.01.004.

Epigenetic regulation of neuroblastoma development.

Durinck K, Speleman F

Cell and tissue research 2018; (372(2)):309-324 doi:10.1007/s00441-017-2773-y.

Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.

Elzomor H, Ahmed G, Elmenawi S, et al.

Journal of the Egyptian National Cancer Institute 2018; (30(1)):21-26 doi:10.1016/j.jnci.2018.01.001.

Origin and initiation mechanisms of neuroblastoma.

Tsubota S, Kadomatsu K

Cell and tissue research 2018; (372(2)):211-221 doi:10.1007/s00441-018-2796-z.

Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

Lee JW, Son MH, Cho HW, et al.

Pediatric blood & cancer 2018; (65(10)):e27257 doi:10.1002/pbc.27257.

Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

Kerosuo L, Neppala P, Hsin J, et al.

Proceedings of the National Academy of Sciences of the United States of America 2018; (115(31)):E7351-E7360 doi:10.1073/pnas.1800039115.

Late Effects and Survivorship Issues in Patients with Neuroblastoma.

Friedman DN, Henderson TO

Children (Basel, Switzerland) 2018; (5(8)) doi:10.3390/children5080107.

High-Risk Neuroblastoma Treatment Review.

Smith V, Foster J

Children (Basel, Switzerland) 2018; (5(9)) doi:10.3390/children5090114.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Siebert N, Troschke-Meurer S, Marx M, et al.

Cancers 2018; (10(10)) doi:10.3390/cancers10100387.

Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.

Yao W, Li K, Dong KR, et al.

World journal of pediatrics : WJP 2019; (15(2)):148-152 doi:10.1007/s12519-018-0205-z.

Chromosome instability in neuroblastoma.

Fusco P, Esposito MR, Tonini GP

Oncology letters 2018; (16(6)):6887-6894 doi:10.3892/ol.2018.9545.

Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.

Meany HJ

Children (Basel, Switzerland) 2019; (6(1)) doi:10.3390/children6010005.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, et al.

The Lancet. Haematology 2019; (6(5)):e266-e275 doi:10.1016/S2352-3026(19)30023-7.

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Campbell K, Shyr D, Bagatell R, et al.

Pediatric blood & cancer 2019; (66(8)):e27819 doi:10.1002/pbc.27819.

A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease.

Caroleo AM, De Bernardi B, Avanzini S, et al.

Journal of pediatric hematology/oncology 2020; (42(6)):e483-e487 doi:10.1097/MPH.0000000000001517.

Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.

Chami R, Marrano P, Teerapakpinyo C, et al.

The American journal of surgical pathology 2019; (43(9)):1203-1211 doi:10.1097/PAS.0000000000001322.

Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.

Iehara T, Yoneda A, Yokota I, et al.

Pediatric blood & cancer 2019; (66(11)):e27914 doi:10.1002/pbc.27914.

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Park JR, Kreissman SG, London WB, et al.

JAMA 2019; (322(8)):746-755 doi:10.1001/jama.2019.11642.

Neuroblastoma image-defined risk factors in adrenal neuroblastoma: role of radiologist.

Lanza C, Galeazzi V, Carboni N, et al.

Gland surgery 2019; (8(Suppl 3)):S168-S177 doi:10.21037/gs.2019.06.01.

Neurologic disorders in long-term survivors of neuroblastoma - a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program.

Norsker FN, Rechnitzer C, Andersen EW, et al.

Acta oncologica (Stockholm, Sweden) 2020; (59(2)):134-140 doi:10.1080/0284186X.2019.1672892.

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.

Tas ML, Nagtegaal M, Kraal KCJM, et al.

Pediatric blood & cancer 2020; (67(4)):e28061 doi:10.1002/pbc.28061.

Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells.

Zhang C, Xiong X, Li Y, et al.

Oncology letters 2019; (18(6)):6525-6535 doi:10.3892/ol.2019.11020.

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients.

Dalla Palma B, Accardi F, Prezioso L, et al.

Leukemia & lymphoma 2020; (61(5)):1238-1241 doi:10.1080/10428194.2019.1706735.

Genetic predisposition and chromosome instability in neuroblastoma.

Tonini GP, Capasso M

Cancer metastasis reviews 2020; (39(1)):275-285 doi:10.1007/s10555-020-09843-4.

Pediatric neuroblastic tumors: A critical evaluation of cytomorphological features for risk stratification on aspiration cytology.

Behera G, Chhabra G, Mishra P, Sable M

Diagnostic cytopathology 2020; (48(5)):464-474 doi:10.1002/dc.24389.

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.

Zeineldin M, Federico S, Chen X, et al.

Nature communications 2020; (11(1)):913 doi:10.1038/s41467-020-14682-6.

Role and toxicity of radiation therapy in neuroblastoma patients: A literature review.

Zhao Q, Liu Y, Zhang Y, et al.

Critical reviews in oncology/hematology 2020; (149()):102924 doi:10.1016/j.critrevonc.2020.102924.

Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.

Jain R, Hans R, Totadri S, et al.

Pediatric blood & cancer 2020; (67(6)):e28273 doi:10.1002/pbc.28273.

Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

Sokol E, Desai AV, Applebaum MA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(17)):1906-1918 doi:10.1200/JCO.19.03285.

A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol.

Iehara T, Yoneda A, Kikuta A, et al.

BMC pediatrics 2020; (20(1)):212 doi:10.1186/s12887-020-02061-5.

How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival in patients with neuroblastoma? A systematic review and meta-analysis.

Parhar D, Joharifard S, Lo AC, et al.

Pediatric surgery international 2020; (36(8)):897-907 doi:10.1007/s00383-020-04696-y.

Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity.

Yang CL, Serra-Roma A, Gualandi M, et al.

Oncotarget 2020; (11(24)):2357-2371 doi:10.18632/oncotarget.27636.

The Acceptability and Impact of the Xploro Digital Therapeutic Platform to Inform and Prepare Children for Planned Procedures in a Hospital: Before and After Evaluation Study.

Bray L, Sharpe A, Gichuru P, et al.

Journal of medical Internet research 2020; (22(8)):e17367 doi:10.2196/17367.

Stage 4S Neuroblastoma: What Are the Outcomes? A Systematic Review of Published Studies.

Raitio A, Rice MJ, Mullassery D, Losty PD

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie 2021; (31(5)):385-389 doi:10.1055/s-0040-1716836.

Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma.

Dong R, Yang R, Zhan Y, et al.

Cancer cell 2020; (38(5)):716-733.e6 doi:10.1016/j.ccell.2020.08.014.

Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

Liang WH, Federico SM, London WB, et al.

JCO clinical cancer informatics 2020; (4()):895-905 doi:10.1200/CCI.20.00074.

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma.

Zirngibl F, Flemmig C, Lang P, et al.

Children (Basel, Switzerland) 2020; (7(11)) doi:10.3390/children7110198.

Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.

Siebert N, Zumpe M, von Lojewski L, et al.

Oncoimmunology 2020; (9(1)):1836768 doi:10.1080/2162402X.2020.1836768.

Chromaffin Cells with Sympathoblast Signature: Too Similar to Keep Apart?

Bedoya-Reina OC, Schlisio S

Cancer cell 2021; (39(2)):134-135 doi:10.1016/j.ccell.2020.12.009.

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

Yu AL, Gilman AL, Ozkaynak MF, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(8)):2179-2189 doi:10.1158/1078-0432.CCR-20-3909.

Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.

Nakazawa A

Pathology international 2021; (71(4)):232-244 doi:10.1111/pin.13085.

Management of Neuroblastoma in Pediatric Patients.

Croteau N, Nuchtern J, LaQuaglia MP

Surgical oncology clinics of North America 2021; (30(2)):291-304 doi:10.1016/j.soc.2020.11.010.

Neuroblastoma.

Chung C, Boterberg T, Lucas J, et al.

Pediatric blood & cancer 2021; (68 Suppl 2()):e28473 doi:10.1002/pbc.28473.

The patient perspective in the era of personalized medicine: What about scanxiety?

Custers JAE, Davis L, Messiou C, et al.

Cancer medicine 2021; (10(9)):2943-2945 doi:10.1002/cam4.3889.

Exosomes from Plasma of Neuroblastoma Patients Contain Doublestranded DNA Reflecting the Mutational Status of Parental Tumor Cells.

Degli Esposti C, Iadarola B, Maestri S, et al.

International journal of molecular sciences 2021; (22(7)) doi:10.3390/ijms22073667.

Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma.

Ferris MJ, Tian S, Switchenko JM, et al.

Journal of radiation oncology 2018; (7(2)):187-193 doi:10.1007/s13566-018-0349-4.

Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.

Mansfield SA, McCarville MB, Lucas JT, et al.

Annals of surgical oncology 2022; (29(1)):661-670 doi:10.1245/s10434-021-10386-3.

Differential Impact of ALK Mutations in Neuroblastoma.

O'Donohue T, Gulati N, Mauguen A, et al.

JCO precision oncology 2021; (5()) doi:10.1200/PO.20.00181.

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.

Irwin MS, Naranjo A, Zhang FF, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(29)):3229-3241 doi:10.1200/JCO.21.00278.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

Mitosis-Karyorrhexis Index evaluation by digital image visual analysis for application of International Neuroblastoma Pathology Classification in FNA biopsy.

Bhardwaj N, Rohilla M, Trehan A, et al.

Cancer cytopathology 2022; (130(2)):128-135 doi:10.1002/cncy.22520.

Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.

Shimada H, Ikegaki N

Biomolecules 2022; (12(1)) doi:10.3390/biom12010079.

Neuroblastoma survivors at risk for developing subsequent neoplasms: A systematic review.

Westerveld ASR, van Dalen EC, Asogwa OA, et al.

Cancer treatment reviews 2022; (104()):102355 doi:10.1016/j.ctrv.2022.102355.

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study.

Zolk O, von dem Knesebeck A, Graf N, et al.

JMIR research protocols 2022; (11(2)):e27898 doi:10.2196/27898.

MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma.

Bhardwaj N, Rohilla M, Trehan A, et al.

Journal of clinical pathology 2023; (76(9)):599-605 doi:10.1136/jclinpath-2022-208177.

Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand.

Suwannaying K, Techavichit P, Komvilaisak P, et al.

Clinical and experimental pediatrics 2022; (65(9)):453-458 doi:10.3345/cep.2022.00437.

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review.

Mora J

Cancers 2022; (14(11)) doi:10.3390/cancers14112572.

Changes in image-defined risk factors with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma.

Wang H, Chen X, Zhu J, et al.

Abdominal radiology (New York) 2022; (47(10)):3520-3530 doi:10.1007/s00261-022-03596-0.

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.

Cai J, Jacob S, Kurupi R, et al.

Cell reports 2022; (40(4)):111095 doi:10.1016/j.celrep.2022.111095.

Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.

Lai HA, Sharp SE, Bhatia A, et al.

Pediatric blood & cancer 2023; (70 Suppl 4()):e29974 doi:10.1002/pbc.29974.

The pre-surgical factors that determine the decision to proceed to resection in children diagnosed with high-risk neuroblastoma in a resource limited setting.

van Heerden J, Kruger M, Esterhuizen TM, et al.

Pediatric hematology and oncology 2023; (40(3)):242-257 doi:10.1080/08880018.2022.2137610.

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease.

Fong C, Kushner BH, Di Giannatale A, et al.

Frontiers in oncology 2022; (12()):1106597 doi:10.3389/fonc.2022.1106597.

Study on differentially expressed genes between stage M and stage MS neuroblastoma.

Wu Y, Zhang J

Frontiers in oncology 2022; (12()):1083570 doi:10.3389/fonc.2022.1083570.

Whole-exome sequencing reveals genetic variants in low-risk and high-risk neuroblastoma.

Altun Z, Yuan H, Baran B, et al.

Gene 2023; (860()):147233 doi:10.1016/j.gene.2023.147233.

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.

Pinto N, Naranjo A, Ding X, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(8)):1546-1556 doi:10.1158/1078-0432.CCR-22-3032.

Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.

Pastorino F, Capasso M, Brignole C, et al.

Cancers 2023; (15(3)) doi:10.3390/cancers15030560.

A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.

Li HL, Dong LL, Jin MJ, et al.

Molecules (Basel, Switzerland) 2023; (28(3)) doi:10.3390/molecules28031141.

Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification.

Wieczorek A, Szewczyk K, Klekawka T, et al.

Frontiers in oncology 2023; (13()):1134772 doi:10.3389/fonc.2023.1134772.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Metastasis pattern and prognosis in children with neuroblastoma.

Liu S, Yin W, Lin Y, et al.

World journal of surgical oncology 2023; (21(1)):130 doi:10.1186/s12957-023-03011-y.

Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report.

Kato Y, Kawaguchi H, Sakata N, et al.

Children (Basel, Switzerland) 2023; (10(5)) doi:10.3390/children10050871.

Independent Prognostic Factors and Nomogram Prediction of Cancer-Specific Survival in Postoperative Patients With Spinal Cord Astrocytoma.

Wang Y, Jiao J, Yu T, et al.

Global spine journal 2025; (15(2)):370-381 doi:10.1177/21925682231191094.

Treatment of High-Risk Neuroblastoma.

Krystal J, Foster JH

Children (Basel, Switzerland) 2023; (10(8)) doi:10.3390/children10081302.

Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients.

He M, Cai JB, Wu X, et al.

World journal of pediatrics : WJP 2024; (20(3)):250-258 doi:10.1007/s12519-023-00773-z.

Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects.

Makimoto A, Fujisaki H, Matsumoto K, et al.

Cancers 2024; (16(3)) doi:10.3390/cancers16030544.

Local control and toxicity outcomes following consolidative radiation therapy in patients with high-risk neuroblastoma: a 20-year experience at a single center.

Jang JY, Park JH, Kim YJ, et al.

The Turkish journal of pediatrics 2024; (66(1)):99-109.

Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.

Barr EK, Naranjo A, Twist CJ, et al.

Pediatric blood & cancer 2024; (71(8)):e31089 doi:10.1002/pbc.31089.

Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study.

Westerveld ASR, Tytgat GAM, van Santen HM, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(2)):154-166 doi:10.1200/JCO.23.01430.

Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs.

Nong J, Su C, Li C, et al.

EClinicalMedicine 2025; (79()):102964 doi:10.1016/j.eclinm.2024.102964.

Global, regional and national burden of neuroblastoma and other peripheral nervous system tumors, 1990 to 2021 and predictions to 2035: visualizing epidemiological characteristics based on GBD 2021.

Yue C, Zhang Q, Sun F, Pan Q

Neoplasia (New York, N.Y.) 2025; (60()):101122 doi:10.1016/j.neo.2025.101122.

Beyond Treatment: Prevalence, Predictors, and Changes in Anxiety and Depression Among Parents of Childhood Cancer Survivors.

Kurz H, Paul V, Nasse ML, et al.

Psycho-oncology 2025; (34(3)):e70115 doi:10.1002/pon.70115.

Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progression.

Milosevic J, Fransson S, Svensson J, et al.

Cancer letters 2025; (625()):217769 doi:10.1016/j.canlet.2025.217769.

Late toxicity after upper abdominal radiotherapy in pediatric Wilms tumor and neuroblastoma survivors. A systematic review on behalf of SIOPEN and SIOP-RTSG.

Wens FSPL, Zonca F, van Tinteren H, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2025; (209()):110961 doi:10.1016/j.radonc.2025.110961.

SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.

Liu M, Lv D, Yan W, et al.

Journal of translational medicine 2025; (23(1)):598 doi:10.1186/s12967-025-06621-0.

Peripheral neuroblastic tumors: tumor biology and its implications for risk stratification.

Anissi Eddaibouni A, Hachimi S, Bennani Guebessi N, et al.

European journal of pediatrics 2025; (184(7)):447 doi:10.1007/s00431-025-06281-8.

The Role of Medical Hypnosis in Alleviating Procedural Anxiety in Pediatric Interventional Radiology: A Pilot Study.

Condé N, Fortin V, Cabrera T

The International journal of clinical and experimental hypnosis 2025; 1-6 doi:10.1080/00207144.2025.2528240.

[An update on the pathology of peripheral neuroblastic tumors].

Gengler C, Boudjemaa S, Gazeu A, Sartelet H

Annales de pathologie 2025; doi:10.1016/j.annpat.2025.06.025.

Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.

Henderson TO, Bardwell JK, Kao PC, et al.

The Lancet. Child & adolescent health 2025; (9(11)):776-786 doi:10.1016/S2352-4642(25)00241-X.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Emergency Surgical Management of Chemotherapy-Induced Tumor Rupture in a Patient with MYCN-Amplified Neuroblastoma: A Case Report.

Ogawa K, Makita S, Utsunomiya A, et al.

Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.25-0473.

Prognostic Value of a Semi-Quantitative Score Based on 123I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy.

Wang X, Wang G, Zhou Z, et al.

Clinical nuclear medicine 2026; doi:10.1097/RLU.0000000000006372.